Entresto Sales 2015 $20million 2016 Forecast $200 million WTF people

Discussion in 'Novartis' started by anonymous, Apr 24, 2016 at 12:41 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Launch Machine FAIL!!!!
     

  2. anonymous

    anonymous Guest

    Lunch machine perhaps
     
  3. anonymous

    anonymous Guest

    Send it back to the kennel. Total dog! Can't fool the doctors, they know crap when they see it.
     
  4. anonymous

    anonymous Guest

    I think the official number was 17 million. But thats up from 16 million that was booked in the fall. So the trend is up.
     
  5. anonymous

    anonymous Guest

    First Qtr 2016 sales are in at 20mm. Goal for 2016 is 200mm. Figure the issue is common math. Also E.H. Has sales data almost down to a daily event... Albeit there are some discrepancies that occur. But the point is the trajectories are there and they are being closely monitored. It's going to be a rough ride.
     
  6. anonymous

    anonymous Guest

    Oops sorry. 17mm sales 1st Qtr 2016. Give or take a few million. Story does change.
     
  7. anonymous

    anonymous Guest

    So if $17 mill was the 1st qtr and 200 mill is the goal...........we need a 1000% increase in sales. Someone check my math.
     
  8. anonymous

    anonymous Guest

    Not to worry. The 17mm in sales was worldwide. Surely the U.S. Sales were at least 5 mm for the qtr.
     
  9. anonymous

    anonymous Guest

    Brand team and marketing huge fail!
     
  10. anonymous

    anonymous Guest

    Unfortunately the company isn't willing to let the reps do what they know how to do. They are trying all these dumb pilot programs when they should have let us choose our own targets for the first 2 trimesters at launch.

    The problem is they forecasted too high from the get go, with the promise to investors that there would be a robust uptake. (Without managed care access) so if you want the best outcome? Let your reps go first to the targets they know are they can move immediately.

    Unfortunately my ABL claims we were given this ability, but would constantly ask, "why aren't we going here there and everywhere" top tier, slow adopting, low to no access offices? And then CPR? Who came up with that idea. 75% was a list of non-prescribers of which more than half was no access. But we needed to figure out how to go there every week. Oh, and don't go to the doctors that are prescribing 15 or more prescriptions. That is the dumbest launch plan ever. So what happens? The extra $ put on the table was a waste for most reps.

    The company used "NOAC" early adopters. They should have looked at Pradaxa, which from the get go had a slower uptake as it was the first to market. But no, they look at the market as a whole along With xarelto and eliquis. Yes, the adoption of the NOACs is now standard. Doctors are still so reserved cause they can't understand, or won't take the time to understand the MOA, and the data.

    The company is requiring more and more day to day. They are spinning the wheel to see what pilot program sticks. Why not let us do our own version of CPR. And put our ABLs and RDs in a closet cause they're just getting in the way. Sending metrics, hiring idiots for partners. I'm so over it.

    I wanted to try and stay at Novartis as frankly my career has truly been decent. But with my manager, and with all that we are being required to do, I think the writing is on the wall. It may be time for that change. Maybe between now and my next chapter, Novartis will downsize so I can get a decent package. Otherwise change is in the works.
     
  11. anonymous

    anonymous Guest

    For EVERY product they're launching. Disaster.
     
  12. anonymous

    anonymous Guest


    A generic drug(s) with very questionable efficacy. Makes you wonder about the doctors who write this crap.
     
  13. anonymous

    anonymous Guest

    Failure to launch. Failure to thrive. It's a failure, plain and simple :oops:
     
  14. anonymous

    anonymous Guest

    Sacubitrilat inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure-lowering peptides that work mainly by reducing blood volume.

    So Sacubitril essentially works as a diuretic reducing blood volume aka Diovan HCT

    What a shock only a few paid morons (speakers) are fleecing patients for a combo med you can get as generic for pennies on the dollar
     
  15. anonymous

    anonymous Guest

    your target list was NOAC writers? Please!
     
  16. anonymous

    anonymous Guest

    I hear things have turned around. The stocks up, thinking about taking a profit. Is Entresto moving?
     
  17. anonymous

    anonymous Guest

    You're kidding, no!?!
     
  18. anonymous

    anonymous Guest

    This poison shows that too many drs are very stupid people. How can they write this shit with a clean conscience? Cant wait for the lawsuits to start.
     
  19. anonymous

    anonymous Guest

    You must be talking to Bob
    Or listening to his Q & A, which is all him talking :eek:
     
  20. anonymous

    anonymous Guest